灯盏生脉胶囊治疗缺血性脑卒中更新证据:系统评价与Meta分析
该系统评价纳入28项RCT共6683例缺血性脑卒中患者,评估灯盏生脉胶囊联合常规治疗的疗效与安全性。结果显示联合治疗可改善Barthel指数、降低改良Rankin量表评分和神经功能缺损评分,降低复发率与死亡率,并改善血液流变学和脂代谢,未报告严重不良事件。
要点
- 灯盏生脉胶囊联合常规治疗可降低缺血性脑卒中复发率(RR 0.57)和死亡率(RR 0.54)。
- 联合治疗改善神经功能缺损评分(WMD -2.81)和日常生活能力(Barthel指数WMD 8.97)。
- 联合治疗对血液流变学和脂代谢有有益影响,未报告严重不良事件。
核心结论
- 灯盏生脉胶囊联合常规治疗缺血性脑卒中在临床应用中似乎安全有效,可降低死亡率、复发率和神经功能缺损评分,改善临床效果和生活质量。
研究设计与样本
- 系统评价与Meta分析,纳入28项随机对照试验(RCT),共6683例参与者,检索8个电子数据库至2021年1月27日。
主要发现
- 与常规治疗组相比,灯盏生脉胶囊联合常规治疗改善Barthel指数(WMD 8.97,95%CI 5.88-12.05)。
- 联合治疗降低改良Rankin量表评分(WMD -0.75,95%CI -1.02至-0.48)和神经功能缺损评分(WMD -2.81,95%CI -4.17至-1.44)。
- 联合治疗降低复发率(RR 0.57,95%CI 0.44-0.73)和死亡率(RR 0.54,95%CI 0.31-0.95),改善临床效果(RR 1.18,95%CI 1.12-1.24)和生活质量(WMD 21.67,95%CI 6.74-36.61)。
- 联合治疗升高APTT(SMD 1.17,95%CI 0.87-1.47)和INR(SMD 1.12,95%CI 0.82-1.42),降低TC(SMD -0.62,95%CI -1.04至-0.20)、TG(SMD -0.72,95%CI -1.18至-0.26)和LDL(SMD -1.14,95%CI -1.57至-0.71),升高HDL(SMD 0.93,95%CI 0.36-1.50)。
- 无试验报告严重不良事件。
临床怎么用
- 在常规治疗基础上加用灯盏生脉胶囊可能有助于改善缺血性脑卒中患者的神经功能、日常生活能力及血脂和血液流变学指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Ischemic stroke is the most common type of stroke, with high mortality, disability and recurrence rate, which brings a heavy burden to individuals, families and the medical system. Therefore, the intervention and treatment of ischemic stroke are of great significance. Chinese herbal medicine is widely used in treating stroke, for example, Dengzhan shengmai (DZSM) capsule. The current systematic review aims to comprehensively evaluate the efficacy and safety of the DZSM capsule in treating ischemic stroke. MATERIALS AND METHODS: Eligible randomized controlled trials (RCTs) were included to evaluate the efficacy and safety of Chinese herbal medicine DZSM capsule in treating ischemic stroke. Eight electronic databases were searched up to January 27, 2021. The risk ratio (RR), standardized mean difference (SMD), or weighted mean difference (WMD) with 95% confidence interval (CI) were used to assess DZSM capsule treatment outcomes. RESULTS: A total of 28 RCTs involving 6683 participants were included in the systematic review and meta-analysis. Compared with conventional therapy group, DZSM capsule plus conventional therapy improved Barthel Index scores (WMD: 8.97, 95%CI: 5.88-12.05) and reduced modified Rankin Scale (WMD: -0.75, 95%CI: -1.02∼ -0.48), reduced neurological functional deficit scores (WMD: -2.81, 95%CI: -4.17∼ -1.44), recurrence rate (RR: 0.57, 95%CI: 0.44-0.73) and mortality (RR: 0.54, 95%CI: 0.31-0.95), improved clinical effect (RR: 1.18, 95%CI: 1.12-1.24) and quality of life (WMD: 21.67, 95%CI: 6.74-36.61), exhibited a beneficial effect on hemorheology such as elevated levels of APTT (SMD: 1.17, 95%CI: 0.87-1.47) and INR (SMD: 1.12, 95%CI: 0.82-1.42), and on lipid metabolism such as levels of TC (SMD: -0.62, 95%CI: -1.04 ∼ -0.20), TG (SMD: -0.72, 95%CI: -1.18∼ -0.26), LDL (SMD: -1.14, 95%CI: -1.57∼ -0.71) and HDL (SMD: 0.93, 95%CI: 0.36-1.50). No trials reported severe adverse events. CONCLUSION: DZSM capsule appears to be safe and effective in clinical applications for ischemic stroke. Based on conventional therapy, adding the DZSM capsule could reduce the mortality, recurrence rate, and neurological functional deficit scores, improve clinical effect and quality of life. In addition, compared with conventional therapy, the addition of the DZSM capsule played a beneficial role in hemorheology and lipid metabolism, which may attribute to the potential mechanism.
引用
- Liu X, Li Y, Bai N, et al. Updated evidence of Dengzhan Shengmai capsule against ischemic stroke: A systematic review and meta-analysis. J Ethnopharmacol. 2021. PMID: 34571078. doi:10.1016/j.jep.2021.114675
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。